VanEck Pharmaceutical ETF (NASDAQ:PPH) Sees Large Increase in Short Interest

VanEck Pharmaceutical ETF (NASDAQ:PPH) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 3,148,062 shares, a growth of 41.9% from the December 15th total of 2,218,941 shares. Based on an average daily volume of 455,352 shares, the short-interest ratio is currently 6.9 days. Currently, 27.4% of the shares of the stock are sold short. Currently, 27.4% of the shares of the stock are sold short. Based on an average daily volume of 455,352 shares, the short-interest ratio is currently 6.9 days.

VanEck Pharmaceutical ETF Stock Performance

VanEck Pharmaceutical ETF stock traded up $0.28 during trading hours on Friday, hitting $105.32. 425,680 shares of the stock were exchanged, compared to its average volume of 406,816. The stock has a market capitalization of $1.20 billion, a P/E ratio of 20.21 and a beta of 0.54. The business’s 50-day moving average is $101.94 and its two-hundred day moving average is $93.66. VanEck Pharmaceutical ETF has a 12 month low of $77.67 and a 12 month high of $107.28.

VanEck Pharmaceutical ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 29th were given a dividend of $0.3106 per share. The ex-dividend date was Monday, December 29th. This represents a $1.24 dividend on an annualized basis and a yield of 1.2%.

Hedge Funds Weigh In On VanEck Pharmaceutical ETF

Institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. increased its position in VanEck Pharmaceutical ETF by 82.4% in the 2nd quarter. Osaic Holdings Inc. now owns 22,125 shares of the company’s stock valued at $1,946,000 after acquiring an additional 9,992 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of VanEck Pharmaceutical ETF by 2,852.2% during the second quarter. JPMorgan Chase & Co. now owns 255,837 shares of the company’s stock worth $22,503,000 after purchasing an additional 247,171 shares in the last quarter. J.Safra Asset Management Corp lifted its position in shares of VanEck Pharmaceutical ETF by 4.4% during the third quarter. J.Safra Asset Management Corp now owns 285,787 shares of the company’s stock worth $25,824,000 after purchasing an additional 12,011 shares in the last quarter. Hudock Inc. acquired a new stake in shares of VanEck Pharmaceutical ETF in the second quarter valued at approximately $811,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of VanEck Pharmaceutical ETF in the second quarter valued at approximately $287,000.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.